Copyright
©The Author(s) 2022.
World J Hepatol. Jan 27, 2022; 14(1): 140-157
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.140
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.140
Vaccine | Phase | Study design | Outcome |
Autologous dendritic cells (DCs) generated ex vivo in the presence of GM-CSF and IL-4[70] | Phase I | 10 patients with unresectable primary liver cancer | Immunization well tolerated without significant toxicity |
Mature autologous DCs[71] | Phase II | To investigate the safety and efficacy of intravenous vaccination | Safe and well tolerated with evidence of antitumor efficacy |
Ilixadencel (pro-inflammatory allogeneic DCs stimulated by GM-CSF and IL-4)[72] | Phase I trial | 17 HCC patients; As monotherapy or in combination with sorafenib to evaluate tolerability | Increased tumor specific CD8+ T cells in peripheral blood (73%); 1 grade 3 adverse event |
GPC3 peptide[67] | Open-label, phase I clinical trial | 33 patients with advanced HCC; To evaluate safety of GPC3 peptide, immune response, tumor response, time to tumor progression, and overall survival | GPC3 vaccination was well-tolerated; 1 patient partial response; 19 patient stable disease; 2 mo after vaccination; Measurable immune responses and antitumor efficacy |
Pexa-Vec (modified poxvirus JX-594)[73] | Randomized phase II dose-finding trial | 30 patients with advanced HCC; 3 intra-tumoral injections; To determine the optimal JX-594 dose | Dose related survival benefit; Increased median survival of 14.1 mo compared to 6.7 mo |
Pexa-Vec (JX-594)[74] | Phase 2, open-label, randomized dose finding study | Patients with advanced HCC; Intra-tumoral injection 3 times every 2 wk | |
Pexa-Vec (pexastimogene devacirepvec) followed by sorafenib[75] | Global, randomized, open-label phase III trial (PHOCUS) | 459 patients will be recruited; To evaluate overall survival, time to progression, progression-free survival, overall response rate and disease control rate | Trial completed; 5% adverse events |
- Citation: Rai V, Mukherjee S. Targets of immunotherapy for hepatocellular carcinoma: An update. World J Hepatol 2022; 14(1): 140-157
- URL: https://www.wjgnet.com/1948-5182/full/v14/i1/140.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i1.140